Ocugen, Inc. filings document the regulatory record for a Nasdaq-listed biotechnology company developing modifier gene therapies for retinal diseases. Form 8-K disclosures cover clinical and Regulation FD updates for programs including OCU410, capital-structure events such as warrant exercises and 6.75% convertible senior notes due 2034, and material agreements tied to the note indenture and loan repayment.
Proxy materials describe annual meeting proposals, shareholder voting matters, and governance practices. Other filings identify the company's common stock on The Nasdaq Capital Market, preliminary financial information, authorized-share validation matters, and furnished investor presentations containing forward-looking clinical-development statements.
Ocugen, Inc. reported results from its 2026 Annual Meeting of Stockholders and confirmed a key leadership change. Stockholders elected Kirsten Castillo and Satish Chandran as Class III directors, with 56,242,944 and 62,604,983 votes in favor, respectively. PricewaterhouseCoopers LLP was ratified as independent auditor for the 2026 fiscal year with 136,784,245 votes for and 1,002,550 against.
Stockholders approved, on an advisory basis, the compensation of the company’s named executive officers, with 49,968,948 votes for and 13,245,090 against. They also indicated a preference to hold future advisory votes on executive pay every year, supported by 57,545,540 votes for a one-year frequency. The Board decided to follow this annual frequency. In addition, Ocugen appointed Mohamed Genead as Chief Medical Officer effective June 11, 2026, transitioning him from his prior Acting/Interim role.
Ocugen, Inc. reports a leadership change in its finance function. Effective May 29, 2026, Ramesh Ramachandran resigned as Chief Accounting Officer, a role that also carried responsibility as principal accounting officer.
Following his resignation, on June 3, 2026, Chief Financial Officer Rita Johnson-Greene was appointed as principal accounting officer. Her employment terms and background were previously described in a Form 8-K filed on February 9, 2026. The company states there are no special arrangements behind her appointment, no family relationships with directors or executives, and no related-party transactions requiring disclosure.
Ocugen, Inc. reported a leadership change in its medical organization. Effective May 8, 2026, Huma Qamar, M.D., MPH, CMI, separated from the company as Chief Medical Officer. On the same date, Ocugen appointed Mohamed Genead, M.D., M.Sc., as Acting/Interim Chief Medical Officer, ensuring continuity of senior medical leadership while the company evaluates longer-term plans for the role.
Ocugen, Inc. closed a private offering of $130.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034, including $15.0 million of additional notes issued from a fully exercised over-allotment option.
The notes cannot be converted before the earlier of May 15, 2027 or a reserved share effective date and will be settled solely in cash until that date. The sale is expected to provide approximately $112.6 million in net proceeds, of which about $32.7 million repaid Ocugen’s Avenue Loan Agreement, with the balance for general corporate purposes. A maximum of 8,108,108 common shares may be issued upon conversion of the additional notes. Management states this financing is expected to extend Ocugen’s cash runway into 2028 to support three late-stage programs and potential BLA filings.
Ocugen, Inc. reported a larger net loss of $19.2 million for the quarter ended March 31, 2026, compared with $15.4 million a year earlier, driven by higher research and development and general and administrative expenses. Collaborative arrangement revenue was stable at $1.5 million, but operating expenses rose to $19.4 million, reflecting advancement of its gene therapy pipeline. Cash was $31.9 million and total assets $56.9 million, against total liabilities of $51.1 million. The company states that existing cash will not fund operations for 12 months after issuance of these financial statements and explicitly discloses substantial doubt about its ability to continue as a going concern, despite recent equity and warrant financings. After quarter‑end, Ocugen issued $115.0 million of 6.75% Convertible Senior Notes due 2034 and used $32.7 million of the proceeds to repay its Avenue Capital term loan.
Ocugen, Inc. completed a private offering of $115.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034, issued under an indenture with U.S. Bank Trust Company as trustee. The notes are unsecured, pay 6.75% interest semi-annually, and mature on May 15, 2034, with conversion into cash and/or common stock allowed after a specified future date, subject to an Exchange Cap and stockholder approval rules.
Ocugen received net proceeds of about $99.5 million after discounts and expenses, using approximately $32.7 million to fully repay and terminate its Avenue Loan Agreement and related loan documents, with the balance earmarked for general corporate purposes. After giving effect to the notes issuance and loan repayment, Ocugen estimates it would have had $99.0 million of cash, cash equivalents, and restricted cash on an as-adjusted basis as of March 31, 2026.
Ocugen, Inc. reported first quarter 2026 results and priced $115.0 million of 6.75% Convertible Senior Notes due 2034 in a private offering. Net proceeds are expected to be about $99.5 million, rising to $112.6 million if the initial purchaser’s option for an additional $15.0 million is fully exercised.
Ocugen plans to use approximately $32.7 million of the proceeds to fully repay its higher-cost Avenue loan and terminate that facility, with the remaining cash supporting general corporate purposes and extending its cash runway into 2028. For Q1 2026, the company generated $1.533 million in collaborative revenue and recorded a net loss of $19.2 million, with cash, cash equivalents, and restricted cash of $32.2 million as of March 31, 2026. After the offering and debt payoff, Ocugen expects cash, cash equivalents, and restricted cash of $112.1 million at closing, and potentially $127.1 million if remaining Janus Henderson warrants are exercised.
Ocugen, Inc. plans a private offering of $115 million aggregate principal amount of convertible senior notes due 2034 to qualified institutional buyers, with an expected 13‑day option for the initial purchaser to buy up to an additional $15 million of notes. The notes will be unsecured senior obligations, convertible into cash, common stock, or a combination at Ocugen’s election, with the interest rate and conversion rate set at pricing. Ocugen intends to use approximately $32.7 million of net proceeds to fully repay its loan under the Avenue Loan Agreement, including accrued interest and fees, and use the remaining proceeds for general corporate purposes. The company estimates unaudited cash, cash equivalents, and restricted cash of about $32.2 million as of March 31, 2026, and had 338,318,899 common shares outstanding as of that date.
Ocugen, Inc. is asking stockholders to vote at its June 11, 2026 virtual annual meeting on four items: electing two Class III directors, ratifying PwC as auditor for 2026, approving executive pay on an advisory basis, and choosing the preferred frequency for future say‑on‑pay votes.
The proxy also highlights major 2025 progress in Ocugen’s modifier gene therapy pipeline, including completion of enrollment in the 140‑patient Phase 3 OCU400 liMeliGhT trial for retinitis pigmentosa, positive Phase 2 OCU410 data in geographic atrophy, and rapid enrollment in the Phase 2/3 GARDian3 trial of OCU410ST for Stargardt disease. Ocugen reports a strong balance sheet supported by a $22.5 million underwritten offering in January 2026 and $15 million from warrant exercises, and details a heavily performance‑based executive compensation program tied to clinical, financial, and talent objectives.